A Phase 2/3 interventional study of Pozelimab in CD55-deficient Protein-losing Enteropathy and CHAPLE, sponsored by Regeneron Pharmaceuticals. Completed at 3 sites in 3 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to determine the effect of pozelimab on active CD55-deficient protein-losing enteropathy (PLE; CHAPLE).
The secondary objectives of the study are:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria apply.
Patients aged 1 year and older with a clinical diagnosis of CD55-deficient PLE disease
Drug: Pozelimab
Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.
Also known as: REGN3918
Percentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24
Normalization of serum albumin was defined as serum albumin within the normal range at least 70 percent (%) of measurements between weeks 12 and 24, and no single albumin measurement of \<2.5 grams per deciliter (g/dL) between weeks 12 and 24, and no requirement for albumin infusion between weeks 12 and 24. Improvement in the following 4 prespecified clinical outcomes that were evaluable for improvement at baseline, without worsening of the others: Daily bowel movement frequency, the presence and severity of facial edema (physician-reported), the presence and severity of peripheral edema (physician-reported), and the participant/caregiver assessment of frequency of problematic abdominal pain. Percentage of participants with active disease at baseline who achieved normalization of serum albumin and improvement in prespecified clinical outcomes at Week 24 were reported.
Time frame: At Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs
TEAEs are defined as AEs that developed or worsened during the on-treatment period. The on-treatment period is defined as the time from first dose of investigational product up to 21 weeks after the last dose of investigational product. Severity of TEAEs was graded according to the following scale: Mild: Does not interfere in a significant manner with the patient's normal functioning level, Moderate: Produces some impairment of functioning but is not hazardous to health and Severe: Produces significant impairment of functioning or incapacitation and is a definite hazard to the participants health.
Time frame: From start of study drug administration up to approximately 144 weeks
Number of Participants With Improvement in Most Bothersome Signs and Symptoms at Week 24
Improvement in most bothersome sign/symptom determined using semi-structured concept elicitation interview, from 'core' clinical endpoints of frequency of bowel movements, peripheral edema, facial edema, abdominal pain frequency, nausea, vomiting, stool consistency.
Time frame: At Week 24
Number of Bowel Movements Per Day Based on a 1-week Average up to Week 24
Daily bowel movements captured by e-diary. The number of bowel movements per day was calculated each week of the study. It was based on a 1-week average and calculated as the sum of the number of bowel movements in a given week divided by the number of days with non-missing bowel movement frequency data. If more than 3 days of bowel movement data was missing in a given week, bowel movement frequency data was considered missing for that week.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24
Number of Days Per Week With >=1 Bowel Movement of Loose/Watery Stool Consistency at Week 24
The number of days per week with \>=1 loose/watery bowel movement, is calculated each week of the study as the sum of the number of days with \>=1 loose/watery bowel movement in a given week divided by the number of days with non-missing stool consistency data and then multiplied by 7, is presented. If more than 3 days of stool consistency data was missing in a given week, stool consistency data was considered missing for that week.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24
Number of Participants With Abdominal Ascites at Week 24
The measurement of abdominal ascites (excess abdominal fluid) was based on abdominal circumference. Abdominal circumference was measured regardless of the physician's assessment of the presence or absence of ascites.
Time frame: Baseline up to Week 24
Absolute Value of Albumin at Specified Timepoints up to Week 24
Blood samples were collected from participants at defined time points for the assessment of albumin. Absolute value of albumin at specified timepoints was reported.
Time frame: Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24
Absolute Values of Protein, and Immunoglobulin G (IgG) at Baseline and Week 24
Blood samples were collected from participants at defined time points for the assessment of protein and IgG. Absolutes values of protein and IgG measured as g/L at baseline and Week 24 was reported.
Time frame: Baseline, Week 24
Absolute Values of Immunoglobulin (Ig), Immunoglobulin M (IgM), and Immunoglobulin A (IgA) at Baseline and Week 24
Blood samples were collected from participants at defined time points for the assessment of Ig, IgM and IgA. Absolute value of Ig, IgM and IgA measured as mg/dL at baseline and Week 24 was reported.
Time frame: Baseline, Week 24
Absolute Values of Vitamin B12 at Baseline and Week 24
Blood samples were collected from participants at defined time points for the assessment of vitamin B12. Absolute values of vitamin B12 at baseline and Week 24 was reported.
Time frame: Baseline, Week 24
Absolute Values of Iron and Unsaturated Iron Binding Capacity at Baseline and Week 24
Blood samples were collected from participants at defined time points for the assessment of iron indices. Absolute values of unsaturated iron and unsaturated iron binding capacity measured as micromoles per liter (mcmol/L) at baseline and Week 24 was reported.
Time frame: Baseline, Week 24
Absolute Values of Vitamin B9 up to Week 24
Absolute Values of Vitamin B9 - Central Lab
Time frame: Baseline up to Week 24
Absolute Values of Ferritin at Baseline and Week 24
Blood samples were collected from participants at defined time points for the assessment of iron indices. Absolute values of ferritin was reported.
Time frame: Baseline, Week 24
Absolute Values of Magnesium, Total Cholesterol, and Triglycerides at Week 24
Blood samples were collected from participants at defined time points for the assessment of magnesium, total cholesterol, and triglycerides. Absolute values of magnesium, total cholesterol, and triglycerides measured as mmol/L at baseline and Week 24 was reported.
Time frame: Baseline, Week 24
Change From Baseline in Alpha-1 Antitrypsin Levels in Stool at Week 12 and Week 24
Time frame: Week 12, Week 24
Change From Baseline in Alpha-1 Antitrypsin Levels in Blood at Week 12 and Week 24
Time frame: Week 12, Week 24
Percentage of Participants With Active Disease at Baseline Who Maintained Disease Control
Measured by normalization of serum albumin, no worsening of facial or peripheral edema, increase in bowel movement, or increase in abdominal pain frequency, no increase in dose of permitted concomitant medication for the treatment of PLE at any time as described in the protocol
Time frame: Weeks 12 to 48; Weeks 12 to 144; Weeks 24 to 48; Weeks 48 to 96; Weeks 96 to 144
Change From Baseline in Physician Assessment of Facial Edema Based on a 5-point Likert Rating Scale
The physician assessment of facial edema is based on a 5-point Likert scale ranging from no edema (1) to very severe edema (5).
Time frame: Baseline and Week 144
Change From Baseline in Physician Assessment of Peripheral Edema Based on a 5-point Likert Rating Scale
The physician assessment of peripheral edema is based on a 5-point Likert scale ranging from no edema (1) to very severe edema (5).
Time frame: Baseline and Week 144
Change From Baseline in Food and Drink Limitations as Assessed by the PedsQL™ GI Symptom Scales' Food and Drink Limits Sub-scale
Frequency of limitations is assessed on a 5-point Likert response scale, ranging from never a problem (0) to almost always a problem (4). Items were reverse scored and linearly transformed to a 0 to 100 scale, where lower scores indicate more frequent problems with food and drink limitations.
Time frame: Baseline and Week 144
Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the PedsQL™ Generic Core Scales
Physical functioning, emotional functioning, social functioning, and school/work/studies functioning is assessed using a 5-point Likert scale, ranging from never a problem (0) to almost always a problem (4). Items were reverse-scored and linearly transformed to a 0 to 100 scale, with higher scores indicating better HRQoL. The total scale score is computed as the sum of all the items over the number of items answered on individual scales. Subscale score is calculated as the sum of the items in the scale divided by the number of items answered in the scale.
Time frame: Baseline and Week 144
Number of Participants With Albumin Infusion by 24 Week Periods
Time frame: Weeks 0 to 24; Weeks 24 to 48; Weeks 48 to 72; Weeks 72 to 96; Weeks 96 to 120; Weeks 120 to 144
Change From Baseline in Albumin Values
Time frame: Baseline and Week 144
Percentage Change From Baseline in Albumin Values
Time frame: Baseline and Week 144
Time to First Normalization for Albumin Values
Time frame: Baseline up to Week 144
Change From Baseline in Protein Values
Time frame: Baseline and Week 144
Time to First Normalization for Total Protein
Time frame: Baseline up to Week 144
Change From Baseline in Immunoglobulin (Ig) Values
Time frame: Baseline and Week 144
Time to First Normalization for Ig Values
Time frame: Baseline up to Week 144
Change From Baseline in IgG Values
Time frame: Baseline and Week 144
Time to First Normalization for IgG Values
Time frame: Baseline up to Week 144
Change From Baseline in IgM Values
Time frame: Baseline and Week 144
Time to First Normalization for IgM Values
Time frame: Baseline up to Week 44
Change From Baseline in IgA Values
Time frame: Baseline and Week 144
Time to First Normalization for IgA Values
Time frame: Baseline up to Week 144
Change From Baseline in Vitamin B12 Values
Time frame: Baseline and Week 144
Time to First Normalization for Vitamin B12 Values
Time frame: Baseline up to Week 144
Change From Baseline in Vitamin B9 (Folate) Values
Time frame: Baseline and Week 144
Time to First Normalization for Vitamin B9 (Folate) Values
Time frame: Baseline up to Week 144
Change From Baseline in Iron Values
Time frame: Baseline and Week 144
Time to First Normalization for Iron Values
Time frame: Baseline up to Week 144
Change From Baseline in Unsaturated Iron Binding Capacity
Time frame: Baseline and Week 144
Time to First Normalization for Unsaturated Iron Binding Capacity
Time frame: Baseline up to Week 144
Change From Baseline in Ferritin Values
Time frame: Baseline and Week 144
Time to First Normalization for Ferritin Values
Time frame: Baseline up to Week 144
Change From Baseline in Magnesium Values
Time frame: Baseline and Week 144
Time to First Normalization for Magnesium Values
Time frame: Baseline up to Week 144
Change From Baseline in Fasting Cholesterol Values
Time frame: Baseline and Week 144
Time to First Normalization for Fasting Cholesterol Values
Time frame: Baseline up to Week 144
Change From Baseline in Fasting Triglycerides Values
Time frame: Baseline and Week 144
Time to First Normalization for Fasting Triglycerides Values
Time frame: Baseline up to Week 144
Number of Participants Who Used Concomitant Medication
Time frame: Baseline up to Week 144
Number of Hospitalization Days by 24 Week Period
Time frame: Weeks 0 to 24; Weeks 24 to 48; Weeks 48 to 72; Weeks 72 to 96; Weeks 96 to 120; Weeks 120 to 144
Change From Baseline in Body Weight Z-Score
Weight-for-age z-score compares a participant's weight to children of the same age and sex from a healthy reference population. A z-score reflects an individual score as compared to a population mean and is expressed in units of standard deviation above (positive values) and below (negative values). Body weight z-score, regardless of magnitude, represents catch-up growth.
Time frame: Baseline and Week 144
Change From Baseline in Height Z-Score
Height-for-age z-score compares a participant's height to children of the same age and sex from a healthy reference population. A z-score reflects an individual score as compared to a population mean and is expressed in units of standard deviation above (positive values) and below (negative values). Any increase in height z-score, regardless of magnitude, represents catch-up growth.
Time frame: Baseline and Week 144
Change From Baseline in Total Complement Activity Complement Hemolytic Assay (CH50)
Time frame: Baseline and Week 144
Concentrations of Total Pozelimab in Serum
Time frame: Baseline up to Week 164
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) to Pozelimab
Time frame: Baseline up to Week 164
| Milestone | Pozelimab Injection |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
Normalization of serum albumin was defined as serum albumin within the normal range at least 70 percent (%) of measurements between weeks 12 and 24, and no single albumin measurement of \<2.5 grams per deciliter (g/dL) between weeks 12 and 24, and no requirement for albumin infusion between weeks 12 and 24. Improvement in the following 4 prespecified clinical outcomes that were evaluable for improvement at baseline, without worsening of the others: Daily bowel movement frequency, the presence and severity of facial edema (physician-reported), the presence and severity of peripheral edema (physician-reported), and the participant/caregiver assessment of frequency of problematic abdominal pain. Percentage of participants with active disease at baseline who achieved normalization of serum albumin and improvement in prespecified clinical outcomes at Week 24 were reported.
| percentage of participants | Pozelimab Injection |
|---|---|
| Percentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24 | 100 (74.1 to 100) |
TEAEs are defined as AEs that developed or worsened during the on-treatment period. The on-treatment period is defined as the time from first dose of investigational product up to 21 weeks after the last dose of investigational product. Severity of TEAEs was graded according to the following scale: Mild: Does not interfere in a significant manner with the patient's normal functioning level, Moderate: Produces some impairment of functioning but is not hazardous to health and Severe: Produces significant impairment of functioning or incapacitation and is a definite hazard to the participants health.
| Participants | Pozelimab Injection |
|---|---|
| Participants with TEAEs | 10 |
| Participants with mild severity | 3 |
| Participants with moderate severity | 5 |
| Participants with severe severity | 2 |
Improvement in most bothersome sign/symptom determined using semi-structured concept elicitation interview, from 'core' clinical endpoints of frequency of bowel movements, peripheral edema, facial edema, abdominal pain frequency, nausea, vomiting, stool consistency.
| Participants | Pozelimab Injection |
|---|---|
| Number of Participants With Improvement in Most Bothersome Signs and Symptoms at Week 24 | 10 |
Daily bowel movements captured by e-diary. The number of bowel movements per day was calculated each week of the study. It was based on a 1-week average and calculated as the sum of the number of bowel movements in a given week divided by the number of days with non-missing bowel movement frequency data. If more than 3 days of bowel movement data was missing in a given week, bowel movement frequency data was considered missing for that week.
| Bowel movements per day | Pozelimab Injection |
|---|---|
| Baseline | 1.64 (0.5 to 3.4) |
| Week 1 | 1.13 (0.3 to 3.0) |
| Week 2 | 1.36 (0.7 to 3.4) |
| Week 3 | 1.43 (0.7 to 2.4) |
| Week 4 | 1.50 (0.8 to 2.6) |
| Week 5 | 1.57 (0.5 to 2.3) |
| Week 6 | 1.21 (0.6 to 3.0) |
| Week 7 | 1.21 (0.3 to 2.5) |
| Week 8 | 1.07 (0.2 to 2.3) |
| Week 9 | 1.00 (0.3 to 2.0) |
| Week 10 | 1.00 (0.5 to 1.7) |
| Week 11 | 1.00 (0.2 to 2.0) |
| Week 12 | 0.79 (0.0 to 1.9) |
| Week 13 | 0.93 (0.1 to 2.3) |
| Week 14 | 0.93 (0.3 to 2.1) |
| Week 15 | 1.07 (0.3 to 2.3) |
| Week 16 | 1.10 (0.4 to 2.0) |
| Week 17 | 1.13 (0.3 to 2.0) |
| Week 18 | 1.00 (0.0 to 1.9) |
| Week 19 | 1.00 (0.3 to 1.9) |
| Week 20 | 0.83 (0.2 to 2.1) |
| Week 21 | 1.00 (0.5 to 1.7) |
| Week 22 | 0.83 (0.4 to 1.7) |
| Week 23 | 0.86 (0.5 to 1.8) |
| Week 24 | 0.90 (0.3 to 2.0) |
The number of days per week with \>=1 loose/watery bowel movement, is calculated each week of the study as the sum of the number of days with \>=1 loose/watery bowel movement in a given week divided by the number of days with non-missing stool consistency data and then multiplied by 7, is presented. If more than 3 days of stool consistency data was missing in a given week, stool consistency data was considered missing for that week.
| Days per week | Pozelimab Injection |
|---|---|
| Baseline | 2.00 (0.0 to 7.0) |
| Week 1 | 0.50 (0.0 to 5.0) |
| Week 2 | 0.00 (0.0 to 2.0) |
| Week 3 | 0.00 (0.0 to 3.0) |
| Week 4 | 0.00 (0.0 to 4.0) |
| Week 5 | 0.00 (0.0 to 5.0) |
| Week 6 | 1.20 (0.0 to 5.0) |
| Week 7 | 0.50 (0.0 to 2.8) |
| Week 8 | 0.50 (0.0 to 3.0) |
| Week 9 | 0.50 (0.0 to 3.0) |
| Week 10 | 0.00 (0.0 to 4.0) |
| Week 11 | 1.00 (0.0 to 2.3) |
| Week 12 | 0.00 (0.0 to 2.3) |
| Week 13 | 0.00 (0.0 to 4.0) |
| Week 14 | 1.58 (0.0 to 4.7) |
| Week 15 | 1.00 (0.0 to 7.0) |
| Week 16 | 0.00 (0.0 to 5.8) |
| Week 17 | 1.28 (0.0 to 5.6) |
| Week 18 | 0.50 (0.0 to 7.0) |
| Week 19 | 0.00 (0.0 to 5.0) |
| Week 20 | 0.00 (0.0 to 5.0) |
| Week 21 | 0.00 (0.0 to 6.0) |
| Week 22 | 0.00 (0.0 to 6.0) |
| Week 23 | 0.00 (0.0 to 6.0) |
| Week 24 | 0.00 (0.0 to 5.6) |
The measurement of abdominal ascites (excess abdominal fluid) was based on abdominal circumference. Abdominal circumference was measured regardless of the physician's assessment of the presence or absence of ascites.
| Participants | Pozelimab Injection |
|---|---|
| Number of Participants With Abdominal Ascites at Week 24 | 1 |
Blood samples were collected from participants at defined time points for the assessment of albumin. Absolute value of albumin at specified timepoints was reported.
| g/dL | Pozelimab Injection |
|---|---|
| Baseline | 2.160 ± 0.5296 |
| Day 2 | 2.267 ± 0.4000 |
| Week 1 | 3.311 ± 0.4485 |
| Week 2 | 3.589 ± 0.4428 |
| Week 3 | 4.025 ± 0.3955 |
| Week 4 | 4.167 ± 0.3841 |
| Week 6 | 4.411 ± 0.7026 |
| Week 8 | 4.188 ± 0.3137 |
| Week 10 | 4.322 ± 0.2279 |
| Week 12 | 4.288 ± 0.2748 |
| Week 14 | 4.363 ± 0.2615 |
| Week 16 | 4.367 ± 0.3674 |
| Week 18 | 4.344 ± 0.2555 |
| Week 20 | 4.449 ± 0.2539 |
| Week 22 | 4.422 ± 0.2906 |
| Week 24 | 4.544 ± 0.2603 |
Blood samples were collected from participants at defined time points for the assessment of protein and IgG. Absolutes values of protein and IgG measured as g/L at baseline and Week 24 was reported.
| g/L | Pozelimab Injection |
|---|---|
| Protein at Baseline | 37.50 ± 6.996 |
| Protein at Week 24 | 72.22 ± 4.969 |
| IgG at Baseline | 2.183 ± 0.9103 |
| IgG at Week 24 | 11.301 ± 2.0503 |
Blood samples were collected from participants at defined time points for the assessment of Ig, IgM and IgA. Absolute value of Ig, IgM and IgA measured as mg/dL at baseline and Week 24 was reported.
| mg/dL | Pozelimab Injection |
|---|---|
| Ig at Baseline | 318.2 ± 113.36 |
| Ig at Week 24 | 1430.1 ± 263.36 |
| IgM at Baseline | 52.9 ± 28.36 |
| IgM at Week 24 | 180.3 ± 74.81 |
| IgA at Baseline | 47.0 ± 18.51 |
| IgA at Week 24 | 119.8 ± 52.46 |
Blood samples were collected from participants at defined time points for the assessment of vitamin B12. Absolute values of vitamin B12 at baseline and Week 24 was reported.
| picomoles per liter (pmol/L) | Pozelimab Injection |
|---|---|
| Baseline | 158.5 ± 52.32 |
| Week 24 | 383.1 ± 102.73 |
Blood samples were collected from participants at defined time points for the assessment of iron indices. Absolute values of unsaturated iron and unsaturated iron binding capacity measured as micromoles per liter (mcmol/L) at baseline and Week 24 was reported.
| mcmol/L | Pozelimab Injection |
|---|---|
| Iron at Baseline | 3.40 ± 1.478 |
| Iron at Week 24 | 7.38 ± 5.036 |
| Unsaturated Binding Capacity at Baseline | 38.24 ± 12.357 |
| Unsaturated Iron Binding Capacity at Week 24 | 73.95 ± 12.049 |
Absolute Values of Vitamin B9 - Central Lab
| nanomoles per liter (nmol/L) | Pozelimab Injection |
|---|---|
| Week 1 | 17.80 ± 15.017 |
| Week 4 | 22.07 ± 14.342 |
| Week 8 | 17.32 ± 8.042 |
| Week 12 | 17.89 ± 9.646 |
| Week 16 | 18.01 ± 10.610 |
| Week 20 | 19.91 ± 15.436 |
| Week 24 | 18.93 ± 6.538 |
Blood samples were collected from participants at defined time points for the assessment of iron indices. Absolute values of ferritin was reported.
| microgram per liter (mcg/L) | Pozelimab Injection |
|---|---|
| Baseline | 10.0 ± 5.90 |
| Week 24 | 12.0 ± 7.86 |
Blood samples were collected from participants at defined time points for the assessment of magnesium, total cholesterol, and triglycerides. Absolute values of magnesium, total cholesterol, and triglycerides measured as mmol/L at baseline and Week 24 was reported.
| mmol/L | Pozelimab Injection |
|---|---|
| Magnesium at Baseline | 0.793 ± 0.0381 |
| Magnesium at Week 24 | 0.858 ± 0.0245 |
| Total Cholesterol at Baseline | 3.819 ± 0.8786 |
| Total Cholesterol at Week 24 | 3.604 ± 0.3118 |
| Triglycerides at Baseline | 2.033 ± 0.7946 |
| Triglycerides at Week 24 | 1.094 ± 0.3745 |
| milligrams per deciliter (mg/dL) | Pozelimab Injection |
|---|---|
| Change from Baseline to Week 12 | -527.80 ± 318.818 |
| Change from Baseline to Week 24 | -463.71 ± 204.250 |
| mg/dL | Pozelimab Injection |
|---|---|
| Change from Baseline to Week 12 | -57.8 ± 33.15 |
| Change from Baseline to Week 24 | -43.4 ± 35.89 |
Measured by normalization of serum albumin, no worsening of facial or peripheral edema, increase in bowel movement, or increase in abdominal pain frequency, no increase in dose of permitted concomitant medication for the treatment of PLE at any time as described in the protocol
| percentage of participants | Pozelimab Injection |
|---|---|
| Weeks 12 to 48 | 100 |
| Weeks 12 to 144 | 100 |
| Weeks 24 to 48 | 100 |
| Weeks 48 to 96 | 100 |
| Weeks 96 to 144 | 100 |
The physician assessment of facial edema is based on a 5-point Likert scale ranging from no edema (1) to very severe edema (5).
| score on a scale | Pozelimab Injection |
|---|---|
| Change From Baseline in Physician Assessment of Facial Edema Based on a 5-point Likert Rating Scale | -1.7 ± 0.87 |
The physician assessment of peripheral edema is based on a 5-point Likert scale ranging from no edema (1) to very severe edema (5).
| score on a scale | Pozelimab Injection |
|---|---|
| Change From Baseline in Physician Assessment of Peripheral Edema Based on a 5-point Likert Rating Scale | -1.7 ± 0.71 |
Frequency of limitations is assessed on a 5-point Likert response scale, ranging from never a problem (0) to almost always a problem (4). Items were reverse scored and linearly transformed to a 0 to 100 scale, where lower scores indicate more frequent problems with food and drink limitations.
| score on a scale | Pozelimab Injection |
|---|---|
| Change From Baseline in Food and Drink Limitations as Assessed by the PedsQL™ GI Symptom Scales' Food and Drink Limits Sub-scale | 47.40 ± 36.653 |
Physical functioning, emotional functioning, social functioning, and school/work/studies functioning is assessed using a 5-point Likert scale, ranging from never a problem (0) to almost always a problem (4). Items were reverse-scored and linearly transformed to a 0 to 100 scale, with higher scores indicating better HRQoL. The total scale score is computed as the sum of all the items over the number of items answered on individual scales. Subscale score is calculated as the sum of the items in the scale divided by the number of items answered in the scale.
| score on a scale | Pozelimab Injection |
|---|---|
| Week 144 Change from Baseline Total score of PedsQL Core Score | 26.55 ± 17.023 |
| Week 144 Change from Baseline Subscale score: Physical functioning | 14.45 ± 39.900 |
| Week 144 Change from Baseline Subscale score: Emotional functioning | 26.3 ± 28.88 |
| Week 144 Change from Baseline Subscale score: Social functioning | 30.6 ± 20.43 |
| Week 144 Change from Baseline Subscale score: School functioning | 41.43 ± 19.518 |
| Participants | Pozelimab Injection |
|---|---|
| Weeks 0 to 24 | 1 |
| Weeks 24 to 48 | 0 |
| Weeks 48 to 72 | 0 |
| Weeks 72 to 96 | 0 |
| Weeks 96 to 120 | 0 |
| Weeks 120 to 144 | 0 |
| grams per deciliter (g/dL) | Pozelimab Injection |
|---|---|
| Change From Baseline in Albumin Values | 2.400 ± 0.6103 |
| percentage of change | Pozelimab Injection |
|---|---|
| Percentage Change From Baseline in Albumin Values | 127.489 ± 81.0666 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Albumin Values | 15.5 (8 to 28) |
| grams per liter (g/L) | Pozelimab Injection |
|---|---|
| Change From Baseline in Protein Values | 37.13 ± 10.789 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Total Protein | 22.0 (9 to 35) |
| mg/dL | Pozelimab Injection |
|---|---|
| Change From Baseline in Immunoglobulin (Ig) Values | 1271.2 ± 261.91 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Ig Values | 341 (341 to 341) |
| g/L | Pozelimab Injection |
|---|---|
| Change From Baseline in IgG Values | 10.626 ± 2.2486 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for IgG Values | 29.0 (8 to 29) |
| mg/dL | Pozelimab Injection |
|---|---|
| Change From Baseline in IgM Values | 112.0 ± 51.21 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for IgM Values | 1 (1 to 9) |
| mg/dL | Pozelimab Injection |
|---|---|
| Change From Baseline in IgA Values | 96.7 ± 28.78 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for IgA Values | 1 (1 to 9) |
| picomoles per liter (pmol/L) | Pozelimab Injection |
|---|---|
| Change From Baseline in Vitamin B12 Values | 138.8 ± 56.07 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Vitamin B12 Values | 8 (1 to 8) |
| nanomole per liter (nmol/L) | Pozelimab Injection |
|---|---|
| Change From Baseline in Vitamin B9 (Folate) Values | 2.92 ± 10.241 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Vitamin B9 (Folate) Values | 1 (1 to 8) |
| micromole/liter (umol/L) | Pozelimab Injection |
|---|---|
| Change From Baseline in Iron Values | 7.82 ± 4.091 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Iron Values | 97.5 (1 to 337) |
| umol/L | Pozelimab Injection |
|---|---|
| Change From Baseline in Unsaturated Iron Binding Capacity | 16.20 ± 13.811 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Unsaturated Iron Binding Capacity | 1 (1 to 56) |
| microgram per liter (ug/L) | Pozelimab Injection |
|---|---|
| Change From Baseline in Ferritin Values | 32.0 ± 23.67 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Ferritin Values | 28 (1 to 505) |
| millimoles per liter (mmol/L) | Pozelimab Injection |
|---|---|
| Change From Baseline in Magnesium Values | 0.083 ± 0.0606 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Magnesium Values | 1 (1 to 2) |
| mmol/L | Pozelimab Injection |
|---|---|
| Change From Baseline in Fasting Cholesterol Values | -0.072 ± 0.7299 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Fasting Cholesterol Values | 1 (1 to 29) |
| mmol/L | Pozelimab Injection |
|---|---|
| Change From Baseline in Fasting Triglycerides Values | -0.710 ± 0.9086 |
| days | Pozelimab Injection |
|---|---|
| Time to First Normalization for Fasting Triglycerides Values | 4 (1 to 57) |
| Participants | Pozelimab Injection |
|---|---|
| Number of Participants Who Used Concomitant Medication | 10 |
| days | Pozelimab Injection |
|---|---|
| Weeks 0 to 24 | 0.0 (0 to 4) |
| Weeks 24 to 48 | 0.0 (0 to 0) |
| Weeks 48 to 72 | 0.0 (0 to 0) |
| Weeks 72 to 96 | 0.0 (0 to 0) |
| Weeks 96 to 120 | 0.0 (0 to 2) |
| Weeks 120 to 144 | 0.0 (0 to 0) |
Weight-for-age z-score compares a participant's weight to children of the same age and sex from a healthy reference population. A z-score reflects an individual score as compared to a population mean and is expressed in units of standard deviation above (positive values) and below (negative values). Body weight z-score, regardless of magnitude, represents catch-up growth.
| z-score | Pozelimab Injection |
|---|---|
| Change From Baseline in Body Weight Z-Score | 0.924 ± 0.7529 |
Height-for-age z-score compares a participant's height to children of the same age and sex from a healthy reference population. A z-score reflects an individual score as compared to a population mean and is expressed in units of standard deviation above (positive values) and below (negative values). Any increase in height z-score, regardless of magnitude, represents catch-up growth.
| z-score | Pozelimab Injection |
|---|---|
| Change From Baseline in Height Z-Score | 1.079 ± 0.6469 |
| international units/milliliter (IU/mL) | Pozelimab Injection |
|---|---|
| Change From Baseline in Total Complement Activity Complement Hemolytic Assay (CH50) | -241.6 ± 39.79 |
| mg/L | Pozelimab Injection |
|---|---|
| Week 1 | 182 ± 68.9 |
| Week 2 | 185 ± 103 |
| Week 4 | 227 ± 110 |
| Week 6 | 268 ± 106 |
| Week 8 | 306 ± 111 |
| Week 12 | 341 ± 115 |
| Week 16 | 402 ± 141 |
| Week 20 | 418 ± 136 |
| Week 24 | 421 ± 129 |
| Week 36 | 467 ± 127 |
| Week 48 | 517 ± 142 |
| Week 72 | 492 ± 131 |
| Week 96 | 461 ± 115 |
| Week 144 | 430 ± 134 |
| Week 145 | NA ± NA |
| Week 146 | NA ± NA |
| Week 164 | 410 ± 104 |
| Participants | Pozelimab Injection |
|---|---|
| Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) to Pozelimab | 0 |
Collected over From signing of informed consent up to 164 weeks (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pozelimab Injection | 0/10 (0%) | 5/10 (50%) | 10/10 (100%) |
| Event | Pozelimab Injection |
|---|---|
| VomitingGastrointestinal disorders | 2/10 |
| DehydrationMetabolism and nutrition disorders | 1/10 |
| Abdominal painGastrointestinal disorders | 1/10 |
| Head injuryInjury, poisoning and procedural complications | 1/10 |
| Upper limb fractureInjury, poisoning and procedural complications | 1/10 |
| Urinary tract infectionInfections and infestations | 1/10 |
| Event | Pozelimab Injection |
|---|---|
| Abdominal painGastrointestinal disorders | 4/10 |
| VomitingGastrointestinal disorders | 4/10 |
| NasopharyngitisInfections and infestations | 3/10 |
| Upper respiratory tract infectionInfections and infestations | 3/10 |
| RhinitisInfections and infestations | 2/10 |
| AcarodermatitisInfections and infestations | 2/10 |
| PyrexiaGeneral disorders | 2/10 |
| HeadacheNervous system disorders | 2/10 |
| COVID-19Infections and infestations | 2/10 |
| ContusionInjury, poisoning and procedural complications | 2/10 |
The full analysis set (FAS) included all enrolled participants who received the study drug.
| Age, Continuous(years) | Pozelimab Injection |
|---|---|
| Mean | 9.3 ± 4.88 |
| Sex: Female, Male(Participants) | Pozelimab Injection |
|---|---|
| Female | 6 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | Pozelimab Injection |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Pozelimab Injection |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Jan 2020 to primary completion in Nov 2021, 21 months.
Results were first posted in Oct 2023, 1 year 11 months after primary completion. A results delay was requested in Nov 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pozelimab
Protein-Losing Enteropathies